| Diagnostic marker |
Aids the sub-classification of a particular disease state |
INI1 for AT/RT |
[19, 20] |
| Prognostic marker |
Association with some clinical outcome, such as overall survival or recurrence-free survival, independent of the treatment rendered |
IDH mutations in glioma |
[11, 12] |
| Predictive marker |
Predicts the activity of a specific class or type of therapy and helps to make specific treatment decisions |
BRAF V600E mutation in melanoma brain metastases |
[22, 23] |
| Analytical performance |
Accuracy, reliability, repeatability, and reproducibility of an assay |
Analytical performance has not been sufficiently investigated for most biomarkers in neuroonocology |
[1] |
| Clinical performance |
Association of test result with clinical outcome |
MGMT promoter methylation has shown correlation with patient survival times in several studies |
[2, 3, 13] |
| Clinical utility |
Ability to improve clinical decision-making and patient outcomes |
MGMT promoter methylation is not used in the clinical setting in many centers, because the assay has shown insufficient analytical performance |
[4, 6] |
